Selected research
Market Outlook & Growth Opportunities
Global Cystic Fibrosis Drugs Market Outlook and Growth Opportunities 2026
Market perspective
The global Cystic Fibrosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cystic Fibrosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Cystic Fibrosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Cystic Fibrosis Drugs market include Abbott, Johnson & Johnson, Novartis, Vertex Pharmaceuticals, Venus Remedies, United Medical, PTC Therapeutics, Proteostasis Therapeutics and Pharmaxis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Cystic Fibrosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cystic Fibrosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cystic Fibrosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cystic Fibrosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Cystic Fibrosis Drugs Segment by Company
Abbott
Johnson & Johnson
Novartis
Vertex Pharmaceuticals
Venus Remedies
United Medical
PTC Therapeutics
Proteostasis Therapeutics
Pharmaxis
PharmaSwiss
Novo Nordisk
Neovii Biotech
Merck Sharp & Dohme
Insmed
Gilead Sciences
Genzyme
F. Hoffmann-La Roche
Corbus Pharmaceuticals
Chiesi Farmaceutici
Boehringer Ingelheim
Arcturus Therapeutics
Anthera Pharmaceuticals
Actavis
Cystic Fibrosis Drugs Segment by Type
Oral Cystic Fibrosis Drugs
Injection Cystic Fibrosis Drugs
Cystic Fibrosis Drugs Segment by Application
Hospitals
Clinics
Other
Cystic Fibrosis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Cystic Fibrosis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Cystic Fibrosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cystic Fibrosis Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Cystic Fibrosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Cystic Fibrosis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cystic Fibrosis Drugs industry.
Chapter 3: Detailed analysis of Cystic Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Cystic Fibrosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Cystic Fibrosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Cystic Fibrosis Drugs Industry Trends
Table 2. Cystic Fibrosis Drugs Industry Drivers
Table 3. Cystic Fibrosis Drugs Industry Opportunities and Challenges
Table 4. Cystic Fibrosis Drugs Industry Restraints
Table 5. Global Cystic Fibrosis Drugs Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Cystic Fibrosis Drugs Revenue Share by Company (2021-2026)
Table 7. Global Cystic Fibrosis Drugs Sales Volume by Company (K Units) & (2021-2026)
Table 8. Global Cystic Fibrosis Drugs Sales Volume Share by Company (2021-2026)
Table 9. Global Cystic Fibrosis Drugs Average Price (US$/Unit) of Company (2021-2026)
Table 10. Global Cystic Fibrosis Drugs Company Ranking, (2024-2026) & (USD Million)
Table 11. Global Cystic Fibrosis Drugs Key Company Manufacturing Base & Headquarters
Table 12. Global Cystic Fibrosis Drugs Company, Product Type & Application
Table 13. Global Cystic Fibrosis Drugs Company Establishment Date
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Cystic Fibrosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Significant Companies of Oral Cystic Fibrosis Drugs
Table 18. Significant Companies of Injection Cystic Fibrosis Drugs
Table 19. Global Cystic Fibrosis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units)
Table 20. Global Cystic Fibrosis Drugs Sales Volume by Type (2021-2026) & (K Units)
Table 21. Global Cystic Fibrosis Drugs Sales Volume by Type (2027-2032) & (K Units)
Table 22. Global Cystic Fibrosis Drugs Sales Volume Share by Type (2021-2026)
Table 23. Global Cystic Fibrosis Drugs Sales Volume Share by Type (2027-2032)
Table 24. Global Cystic Fibrosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Cystic Fibrosis Drugs Sales Value by Type (2021-2026) & (US$ Million)
Table 26. Global Cystic Fibrosis Drugs Sales Value by Type (2027-2032) & (US$ Million)
Table 27. Global Cystic Fibrosis Drugs Sales Value Share by Type (2021-2026)
Table 28. Global Cystic Fibrosis Drugs Sales Value Share by Type (2027-2032)
Table 29. Significant Companies of Hospitals
Table 30. Significant Companies of Clinics
Table 31. Significant Companies of Other
Table 32. Global Cystic Fibrosis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units)
Table 33. Global Cystic Fibrosis Drugs Sales Volume by Application (2021-2026) & (K Units)
Table 34. Global Cystic Fibrosis Drugs Sales Volume by Application (2027-2032) & (K Units)
Table 35. Global Cystic Fibrosis Drugs Sales Volume Share by Application (2021-2026)
Table 36. Global Cystic Fibrosis Drugs Sales Volume Share by Application (2027-2032)
Table 37. Global Cystic Fibrosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Cystic Fibrosis Drugs Sales Value by Application (2021-2026) & (US$ Million)
Table 39. Global Cystic Fibrosis Drugs Sales Value by Application (2027-2032) & (US$ Million)
Table 40. Global Cystic Fibrosis Drugs Sales Value Share by Application (2021-2026)
Table 41. Global Cystic Fibrosis Drugs Sales Value Share by Application (2027-2032)
Table 42. Global Cystic Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 43. Global Cystic Fibrosis Drugs Sales by Region (2021-2026) & (K Units)
Table 44. Global Cystic Fibrosis Drugs Sales Market Share by Region (2021-2026)
Table 45. Global Cystic Fibrosis Drugs Sales by Region (2027-2032) & (K Units)
Table 46. Global Cystic Fibrosis Drugs Sales Market Share by Region (2027-2032)
Table 47. Global Cystic Fibrosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 48. Global Cystic Fibrosis Drugs Sales Value by Region (2021-2026) & (US$ Million)
Table 49. Global Cystic Fibrosis Drugs Sales Value Share by Region (2021-2026)
Table 50. Global Cystic Fibrosis Drugs Sales Value by Region (2027-2032) & (US$ Million)
Table 51. Global Cystic Fibrosis Drugs Sales Value Share by Region (2027-2032)
Table 52. Global Cystic Fibrosis Drugs Market Average Price (US$/Unit) by Region (2021-2026)
Table 53. Global Cystic Fibrosis Drugs Market Average Price (US$/Unit) by Region (2027-2032)
Table 54. Global Cystic Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Global Cystic Fibrosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 56. Global Cystic Fibrosis Drugs Sales by Country (2021-2026) & (K Units)
Table 57. Global Cystic Fibrosis Drugs Sales Market Share by Country (2021-2026)
Table 58. Global Cystic Fibrosis Drugs Sales by Country (2027-2032) & (K Units)
Table 59. Global Cystic Fibrosis Drugs Sales Market Share by Country (2027-2032)
Table 60. Global Cystic Fibrosis Drugs Sales Value by Country (2021-2026) & (US$ Million)
Table 61. Global Cystic Fibrosis Drugs Sales Value Market Share by Country (2021-2026)
Table 62. Global Cystic Fibrosis Drugs Sales Value by Country (2027-2032) & (US$ Million)
Table 63. Global Cystic Fibrosis Drugs Sales Value Market Share by Country (2027-2032)
Table 64. Abbott Company Information
Table 65. Abbott Business Overview
Table 66. Abbott Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 67. Abbott Cystic Fibrosis Drugs Product Portfolio
Table 68. Abbott Recent Development
Table 69. Johnson & Johnson Company Information
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 72. Johnson & Johnson Cystic Fibrosis Drugs Product Portfolio
Table 73. Johnson & Johnson Recent Development
Table 74. Novartis Company Information
Table 75. Novartis Business Overview
Table 76. Novartis Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Novartis Cystic Fibrosis Drugs Product Portfolio
Table 78. Novartis Recent Development
Table 79. Vertex Pharmaceuticals Company Information
Table 80. Vertex Pharmaceuticals Business Overview
Table 81. Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 83. Vertex Pharmaceuticals Recent Development
Table 84. Venus Remedies Company Information
Table 85. Venus Remedies Business Overview
Table 86. Venus Remedies Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Venus Remedies Cystic Fibrosis Drugs Product Portfolio
Table 88. Venus Remedies Recent Development
Table 89. United Medical Company Information
Table 90. United Medical Business Overview
Table 91. United Medical Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. United Medical Cystic Fibrosis Drugs Product Portfolio
Table 93. United Medical Recent Development
Table 94. PTC Therapeutics Company Information
Table 95. PTC Therapeutics Business Overview
Table 96. PTC Therapeutics Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. PTC Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 98. PTC Therapeutics Recent Development
Table 99. Proteostasis Therapeutics Company Information
Table 100. Proteostasis Therapeutics Business Overview
Table 101. Proteostasis Therapeutics Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 103. Proteostasis Therapeutics Recent Development
Table 104. Pharmaxis Company Information
Table 105. Pharmaxis Business Overview
Table 106. Pharmaxis Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Pharmaxis Cystic Fibrosis Drugs Product Portfolio
Table 108. Pharmaxis Recent Development
Table 109. PharmaSwiss Company Information
Table 110. PharmaSwiss Business Overview
Table 111. PharmaSwiss Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. PharmaSwiss Cystic Fibrosis Drugs Product Portfolio
Table 113. PharmaSwiss Recent Development
Table 114. Novo Nordisk Company Information
Table 115. Novo Nordisk Business Overview
Table 116. Novo Nordisk Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Novo Nordisk Cystic Fibrosis Drugs Product Portfolio
Table 118. Novo Nordisk Recent Development
Table 119. Neovii Biotech Company Information
Table 120. Neovii Biotech Business Overview
Table 121. Neovii Biotech Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Neovii Biotech Cystic Fibrosis Drugs Product Portfolio
Table 123. Neovii Biotech Recent Development
Table 124. Merck Sharp & Dohme Company Information
Table 125. Merck Sharp & Dohme Business Overview
Table 126. Merck Sharp & Dohme Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolio
Table 128. Merck Sharp & Dohme Recent Development
Table 129. Insmed Company Information
Table 130. Insmed Business Overview
Table 131. Insmed Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Insmed Cystic Fibrosis Drugs Product Portfolio
Table 133. Insmed Recent Development
Table 134. Gilead Sciences Company Information
Table 135. Gilead Sciences Business Overview
Table 136. Gilead Sciences Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Gilead Sciences Cystic Fibrosis Drugs Product Portfolio
Table 138. Gilead Sciences Recent Development
Table 139. Genzyme Company Information
Table 140. Genzyme Business Overview
Table 141. Genzyme Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Genzyme Cystic Fibrosis Drugs Product Portfolio
Table 143. Genzyme Recent Development
Table 144. F. Hoffmann-La Roche Company Information
Table 145. F. Hoffmann-La Roche Business Overview
Table 146. F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolio
Table 148. F. Hoffmann-La Roche Recent Development
Table 149. Corbus Pharmaceuticals Company Information
Table 150. Corbus Pharmaceuticals Business Overview
Table 151. Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 153. Corbus Pharmaceuticals Recent Development
Table 154. Chiesi Farmaceutici Company Information
Table 155. Chiesi Farmaceutici Business Overview
Table 156. Chiesi Farmaceutici Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolio
Table 158. Chiesi Farmaceutici Recent Development
Table 159. Boehringer Ingelheim Company Information
Table 160. Boehringer Ingelheim Business Overview
Table 161. Boehringer Ingelheim Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolio
Table 163. Boehringer Ingelheim Recent Development
Table 164. Arcturus Therapeutics Company Information
Table 165. Arcturus Therapeutics Business Overview
Table 166. Arcturus Therapeutics Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolio
Table 168. Arcturus Therapeutics Recent Development
Table 169. Anthera Pharmaceuticals Company Information
Table 170. Anthera Pharmaceuticals Business Overview
Table 171. Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
Table 173. Anthera Pharmaceuticals Recent Development
Table 174. Actavis Company Information
Table 175. Actavis Business Overview
Table 176. Actavis Cystic Fibrosis Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Actavis Cystic Fibrosis Drugs Product Portfolio
Table 178. Actavis Recent Development
Table 179. Key Raw Materials
Table 180. Raw Materials Key Suppliers
Table 181. Cystic Fibrosis Drugs Distributors List
Table 182. Cystic Fibrosis Drugs Customers List
Table 183. Research Programs/Design for This Report
Table 184. Authors List of This Report
Table 185. Secondary Sources
Table 186. Primary Sources
List of Figures
Figure 1. Cystic Fibrosis Drugs Product Image
Figure 2. Global Cystic Fibrosis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 4. Global Cystic Fibrosis Drugs Sales (2021-2032) & (K Units)
Figure 5. Global Cystic Fibrosis Drugs Sales Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Cystic Fibrosis Drugs Company Revenue Ranking in 2025 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 9. Oral Cystic Fibrosis Drugs Image
Figure 10. Injection Cystic Fibrosis Drugs Image
Figure 11. Global Cystic Fibrosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 12. Global Cystic Fibrosis Drugs Sales Volume Share 2021 VS 2025 VS 2032
Figure 13. Global Cystic Fibrosis Drugs Sales Volume Share by Type (2021-2032)
Figure 14. Global Cystic Fibrosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 15. Global Cystic Fibrosis Drugs Sales Value Share 2021 VS 2025 VS 2032
Figure 16. Global Cystic Fibrosis Drugs Sales Value Share by Type (2021-2032)
Figure 17. Hospitals Image
Figure 18. Clinics Image
Figure 19. Other Image
Figure 20. Global Cystic Fibrosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 21. Global Cystic Fibrosis Drugs Sales Volume Share 2021 VS 2025 VS 2032
Figure 22. Global Cystic Fibrosis Drugs Sales Volume Share by Application (2021-2032)
Figure 23. Global Cystic Fibrosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 24. Global Cystic Fibrosis Drugs Sales Value Share 2021 VS 2025 VS 2032
Figure 25. Global Cystic Fibrosis Drugs Sales Value Share by Application (2021-2032)
Figure 26. Global Cystic Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Figure 27. Global Cystic Fibrosis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032
Figure 28. Global Cystic Fibrosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 29. Global Cystic Fibrosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 30. North America Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 31. North America Cystic Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032
Figure 32. Europe Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 33. Europe Cystic Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032
Figure 34. Asia-Pacific Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 35. Asia-Pacific Cystic Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032
Figure 36. South America Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 37. South America Cystic Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032
Figure 38. Middle East & Africa Cystic Fibrosis Drugs Sales Value (2021-2032) & (US$ Million)
Figure 39. Middle East & Africa Cystic Fibrosis Drugs Sales Value Share by Country (%), 2025 VS 2032
Figure 40. USA Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. USA Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. USA Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. Canada Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. Canada Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. Canada Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. Mexico Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. Mexico Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. Mexico Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. Germany Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. Germany Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. Germany Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. France Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. France Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. France Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. U.K. Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. U.K. Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. U.K. Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Italy Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Italy Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Italy Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Spain Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Spain Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Spain Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. Russia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. Russia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. Russia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Netherlands Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Netherlands Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Netherlands Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. Nordic Countries Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. Nordic Countries Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. Nordic Countries Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. China Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. China Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. China Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. Japan Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. Japan Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. Japan Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. South Korea Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. South Korea Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. South Korea Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. India Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. India Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. India Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Australia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Australia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Australia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Southeast Asia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Southeast Asia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Southeast Asia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Brazil Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Brazil Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Brazil Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Argentina Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Argentina Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Argentina Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Chile Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Chile Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Chile Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Colombia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Colombia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Colombia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. Peru Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. Peru Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. Peru Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Saudi Arabia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Saudi Arabia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Saudi Arabia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. Israel Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. Israel Arabia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. Israel Arabia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. UAE Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. UAE Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. UAE Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Turkey Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 116. Turkey Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 117. Turkey Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 118. Iran Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 119. Iran Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 120. Iran Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 121. Egypt Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 122. Egypt Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 123. Egypt Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 124. Cystic Fibrosis Drugs Value Chain
Figure 125. Manufacturing Cost Structure
Figure 126. Cystic Fibrosis Drugs Sales Mode & Process
Figure 127. Direct Comparison with Distribution Share
Figure 128. Distributors Profiles
Figure 129. Years Considered
Figure 130. Research Process
Figure 131. Key Executives Interviewed
Scope & coverage.
Types
- Oral Cystic Fibrosis Drugs
- Injection Cystic Fibrosis Drugs
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Abbott
- Johnson & Johnson
- Novartis
- Vertex Pharmaceuticals
- Venus Remedies
- United Medical
- PTC Therapeutics
- Proteostasis Therapeutics
- Pharmaxis
- PharmaSwiss
- Novo Nordisk
- Neovii Biotech
- Merck Sharp & Dohme
- Insmed
- Gilead Sciences
- Genzyme
- F. Hoffmann-La Roche
- Corbus Pharmaceuticals
- Chiesi Farmaceutici
- Boehringer Ingelheim
- Arcturus Therapeutics
- Anthera Pharmaceuticals
- Actavis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Cystic Fibrosis Drugs Sales Value (2021-2032)
- 1.2.2 Global Cystic Fibrosis Drugs Sales Volume (2021-2032)
- 1.2.3 Global Cystic Fibrosis Drugs Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Cystic Fibrosis Drugs Market Dynamics
- 2.1 Cystic Fibrosis Drugs Industry Trends
- 2.2 Cystic Fibrosis Drugs Industry Drivers
- 2.3 Cystic Fibrosis Drugs Industry Opportunities and Challenges
- 2.4 Cystic Fibrosis Drugs Industry Restraints
3 Cystic Fibrosis Drugs Market by Company
- 3.1 Global Cystic Fibrosis Drugs Company Revenue Ranking in 2025
- 3.2 Global Cystic Fibrosis Drugs Revenue by Company (2021-2026)
- 3.3 Global Cystic Fibrosis Drugs Sales Volume by Company (2021-2026)
- 3.4 Global Cystic Fibrosis Drugs Average Price by Company (2021-2026)
- 3.5 Global Cystic Fibrosis Drugs Company Ranking (2024-2026)
- 3.6 Global Cystic Fibrosis Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Cystic Fibrosis Drugs Company Product Type and Application
- 3.8 Global Cystic Fibrosis Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Cystic Fibrosis Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Cystic Fibrosis Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Cystic Fibrosis Drugs Market by Type
- 4.1 Cystic Fibrosis Drugs Type Introduction
- 4.1.1 Oral Cystic Fibrosis Drugs
- 4.1.2 Injection Cystic Fibrosis Drugs
- 4.2 Global Cystic Fibrosis Drugs Sales Volume by Type
- 4.2.1 Global Cystic Fibrosis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cystic Fibrosis Drugs Sales Volume by Type (2021-2032)
- 4.2.3 Global Cystic Fibrosis Drugs Sales Volume Share by Type (2021-2032)
- 4.3 Global Cystic Fibrosis Drugs Sales Value by Type
- 4.3.1 Global Cystic Fibrosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Cystic Fibrosis Drugs Sales Value by Type (2021-2032)
- 4.3.3 Global Cystic Fibrosis Drugs Sales Value Share by Type (2021-2032)
5 Cystic Fibrosis Drugs Market by Application
- 5.1 Cystic Fibrosis Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.1.3 Other
- 5.2 Global Cystic Fibrosis Drugs Sales Volume by Application
- 5.2.1 Global Cystic Fibrosis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cystic Fibrosis Drugs Sales Volume by Application (2021-2032)
- 5.2.3 Global Cystic Fibrosis Drugs Sales Volume Share by Application (2021-2032)
- 5.3 Global Cystic Fibrosis Drugs Sales Value by Application
- 5.3.1 Global Cystic Fibrosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Cystic Fibrosis Drugs Sales Value by Application (2021-2032)
- 5.3.3 Global Cystic Fibrosis Drugs Sales Value Share by Application (2021-2032)
6 Cystic Fibrosis Drugs Regional Sales and Value Analysis
- 6.1 Global Cystic Fibrosis Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cystic Fibrosis Drugs Sales by Region (2021-2032)
- 6.2.1 Global Cystic Fibrosis Drugs Sales by Region: 2021-2026
- 6.2.2 Global Cystic Fibrosis Drugs Sales by Region (2027-2032)
- 6.3 Global Cystic Fibrosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Cystic Fibrosis Drugs Sales Value by Region (2021-2032)
- 6.4.1 Global Cystic Fibrosis Drugs Sales Value by Region: 2021-2026
- 6.4.2 Global Cystic Fibrosis Drugs Sales Value by Region (2027-2032)
- 6.5 Global Cystic Fibrosis Drugs Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Cystic Fibrosis Drugs Sales Value (2021-2032)
- 6.6.2 North America Cystic Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Cystic Fibrosis Drugs Sales Value (2021-2032)
- 6.7.2 Europe Cystic Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Cystic Fibrosis Drugs Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Cystic Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Cystic Fibrosis Drugs Sales Value (2021-2032)
- 6.9.2 South America Cystic Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Cystic Fibrosis Drugs Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Cystic Fibrosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Cystic Fibrosis Drugs Country-level Sales and Value Analysis
- 7.1 Global Cystic Fibrosis Drugs Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Cystic Fibrosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Cystic Fibrosis Drugs Sales by Country (2021-2032)
- 7.3.1 Global Cystic Fibrosis Drugs Sales by Country (2021-2026)
- 7.3.2 Global Cystic Fibrosis Drugs Sales by Country (2027-2032)
- 7.4 Global Cystic Fibrosis Drugs Sales Value by Country (2021-2032)
- 7.4.1 Global Cystic Fibrosis Drugs Sales Value by Country (2021-2026)
- 7.4.2 Global Cystic Fibrosis Drugs Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.9.2 France Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.16.2 China Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.19.2 India Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Cystic Fibrosis Drugs Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Cystic Fibrosis Drugs Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Cystic Fibrosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Abbott
- 8.1.1 Abbott Company Information
- 8.1.2 Abbott Business Overview
- 8.1.3 Abbott Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Abbott Cystic Fibrosis Drugs Product Portfolio
- 8.1.5 Abbott Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Cystic Fibrosis Drugs Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Novartis Cystic Fibrosis Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Vertex Pharmaceuticals
- 8.4.1 Vertex Pharmaceuticals Company Information
- 8.4.2 Vertex Pharmaceuticals Business Overview
- 8.4.3 Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.4.5 Vertex Pharmaceuticals Recent Developments
- 8.5 Venus Remedies
- 8.5.1 Venus Remedies Company Information
- 8.5.2 Venus Remedies Business Overview
- 8.5.3 Venus Remedies Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Venus Remedies Cystic Fibrosis Drugs Product Portfolio
- 8.5.5 Venus Remedies Recent Developments
- 8.6 United Medical
- 8.6.1 United Medical Company Information
- 8.6.2 United Medical Business Overview
- 8.6.3 United Medical Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.6.4 United Medical Cystic Fibrosis Drugs Product Portfolio
- 8.6.5 United Medical Recent Developments
- 8.7 PTC Therapeutics
- 8.7.1 PTC Therapeutics Company Information
- 8.7.2 PTC Therapeutics Business Overview
- 8.7.3 PTC Therapeutics Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.7.4 PTC Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.7.5 PTC Therapeutics Recent Developments
- 8.8 Proteostasis Therapeutics
- 8.8.1 Proteostasis Therapeutics Company Information
- 8.8.2 Proteostasis Therapeutics Business Overview
- 8.8.3 Proteostasis Therapeutics Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.8.5 Proteostasis Therapeutics Recent Developments
- 8.9 Pharmaxis
- 8.9.1 Pharmaxis Company Information
- 8.9.2 Pharmaxis Business Overview
- 8.9.3 Pharmaxis Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Pharmaxis Cystic Fibrosis Drugs Product Portfolio
- 8.9.5 Pharmaxis Recent Developments
- 8.10 PharmaSwiss
- 8.10.1 PharmaSwiss Company Information
- 8.10.2 PharmaSwiss Business Overview
- 8.10.3 PharmaSwiss Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.10.4 PharmaSwiss Cystic Fibrosis Drugs Product Portfolio
- 8.10.5 PharmaSwiss Recent Developments
- 8.11 Novo Nordisk
- 8.11.1 Novo Nordisk Company Information
- 8.11.2 Novo Nordisk Business Overview
- 8.11.3 Novo Nordisk Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Novo Nordisk Cystic Fibrosis Drugs Product Portfolio
- 8.11.5 Novo Nordisk Recent Developments
- 8.12 Neovii Biotech
- 8.12.1 Neovii Biotech Company Information
- 8.12.2 Neovii Biotech Business Overview
- 8.12.3 Neovii Biotech Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Neovii Biotech Cystic Fibrosis Drugs Product Portfolio
- 8.12.5 Neovii Biotech Recent Developments
- 8.13 Merck Sharp & Dohme
- 8.13.1 Merck Sharp & Dohme Company Information
- 8.13.2 Merck Sharp & Dohme Business Overview
- 8.13.3 Merck Sharp & Dohme Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolio
- 8.13.5 Merck Sharp & Dohme Recent Developments
- 8.14 Insmed
- 8.14.1 Insmed Company Information
- 8.14.2 Insmed Business Overview
- 8.14.3 Insmed Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Insmed Cystic Fibrosis Drugs Product Portfolio
- 8.14.5 Insmed Recent Developments
- 8.15 Gilead Sciences
- 8.15.1 Gilead Sciences Company Information
- 8.15.2 Gilead Sciences Business Overview
- 8.15.3 Gilead Sciences Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.15.4 Gilead Sciences Cystic Fibrosis Drugs Product Portfolio
- 8.15.5 Gilead Sciences Recent Developments
- 8.16 Genzyme
- 8.16.1 Genzyme Company Information
- 8.16.2 Genzyme Business Overview
- 8.16.3 Genzyme Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.16.4 Genzyme Cystic Fibrosis Drugs Product Portfolio
- 8.16.5 Genzyme Recent Developments
- 8.17 F. Hoffmann-La Roche
- 8.17.1 F. Hoffmann-La Roche Company Information
- 8.17.2 F. Hoffmann-La Roche Business Overview
- 8.17.3 F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.17.4 F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolio
- 8.17.5 F. Hoffmann-La Roche Recent Developments
- 8.18 Corbus Pharmaceuticals
- 8.18.1 Corbus Pharmaceuticals Company Information
- 8.18.2 Corbus Pharmaceuticals Business Overview
- 8.18.3 Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.18.4 Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.18.5 Corbus Pharmaceuticals Recent Developments
- 8.19 Chiesi Farmaceutici
- 8.19.1 Chiesi Farmaceutici Company Information
- 8.19.2 Chiesi Farmaceutici Business Overview
- 8.19.3 Chiesi Farmaceutici Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.19.4 Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolio
- 8.19.5 Chiesi Farmaceutici Recent Developments
- 8.20 Boehringer Ingelheim
- 8.20.1 Boehringer Ingelheim Company Information
- 8.20.2 Boehringer Ingelheim Business Overview
- 8.20.3 Boehringer Ingelheim Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.20.4 Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolio
- 8.20.5 Boehringer Ingelheim Recent Developments
- 8.21 Arcturus Therapeutics
- 8.21.1 Arcturus Therapeutics Company Information
- 8.21.2 Arcturus Therapeutics Business Overview
- 8.21.3 Arcturus Therapeutics Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.21.4 Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolio
- 8.21.5 Arcturus Therapeutics Recent Developments
- 8.22 Anthera Pharmaceuticals
- 8.22.1 Anthera Pharmaceuticals Company Information
- 8.22.2 Anthera Pharmaceuticals Business Overview
- 8.22.3 Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.22.4 Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolio
- 8.22.5 Anthera Pharmaceuticals Recent Developments
- 8.23 Actavis
- 8.23.1 Actavis Company Information
- 8.23.2 Actavis Business Overview
- 8.23.3 Actavis Cystic Fibrosis Drugs Sales, Value and Gross Margin (2021-2026)
- 8.23.4 Actavis Cystic Fibrosis Drugs Product Portfolio
- 8.23.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Cystic Fibrosis Drugs Value Chain Analysis
- 9.1.1 Cystic Fibrosis Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Cystic Fibrosis Drugs Sales Mode & Process
- 9.2 Cystic Fibrosis Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Cystic Fibrosis Drugs Distributors
- 9.2.3 Cystic Fibrosis Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst